Logo
x

Search

Subscribe Now

gilead

Gilead Reports the EMA’s MAA and EU-M4all Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk

Gilead Reports the EMA’s MAA and EU-M4all Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individu...

  • February 25, 2025
Gilead Receives EC’s Conditional Marketing for Seladelpar to Treat Primary Biliary Cholangitis (PBC)

Gilead Receives EC’s Conditional Marketing for Seladelpar to Treat Primary Biliary Cholangitis (PBC)

  • February 21, 2025
Gilead Reports US FDA’s NDA Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk

Gilead Reports US FDA’s NDA Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk

  • February 19, 2025
Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders

  • January 13, 2025
Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets

Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets

  • December 18, 2024
Gilead Receives CHMP's Positive Opinion of Seladelpar to Treat Primary Biliary Cholangitis (PBC)

Gilead Receives CHMP's Positive Opinion of Seladelpar to Treat Primary Biliary Cholangitis (PBC)

  • December 13, 2024
Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets

    Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets

    • December 18, 2024
    Gilead Receives CHMP

      Gilead Receives CHMP's Positive Opinion of Seladelpar to Treat Primary Biliary Cholangitis (PBC)

      • December 13, 2024
      Top 20 Cell and Gene Therapy Companies of 2024

        Top 20 Cell and Gene Therapy Companies of 2024

        • November 28, 2024
        Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024

          Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWee...

          • October 21, 2024
          Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

            Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

            • September 30, 2024
            Top 20 Generic Pharma Companies of 2024

              Top 20 Generic Pharma Companies of 2024

              • September 26, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.